Tasly Pharmaceutical Group Co., Ltd

SHSE:600535 Stock Report

Market Cap: CN¥22.8b

Tasly Pharmaceutical Group Future Growth

Future criteria checks 1/6

Tasly Pharmaceutical Group is forecast to grow earnings and revenue by 15.8% and 6.6% per annum respectively. EPS is expected to grow by 15.7% per annum. Return on equity is forecast to be 11.4% in 3 years.

Key information

15.8%

Earnings growth rate

15.71%

EPS growth rate

Pharmaceuticals earnings growth22.9%
Revenue growth rate6.6%
Future return on equity11.38%
Analyst coverage

Good

Last updated12 Jan 2026

Recent future growth updates

Earnings Miss: Tasly Pharmaceutical Group Co., Ltd Missed EPS By 7.6% And Analysts Are Revising Their Forecasts

Feb 26
Earnings Miss: Tasly Pharmaceutical Group Co., Ltd Missed EPS By 7.6% And Analysts Are Revising Their Forecasts

Recent updates

An Intrinsic Calculation For Tasly Pharmaceutical Group Co., Ltd (SHSE:600535) Suggests It's 23% Undervalued

Mar 25
An Intrinsic Calculation For Tasly Pharmaceutical Group Co., Ltd (SHSE:600535) Suggests It's 23% Undervalued

There May Be Some Bright Spots In Tasly Pharmaceutical Group's (SHSE:600535) Earnings

Mar 03
There May Be Some Bright Spots In Tasly Pharmaceutical Group's (SHSE:600535) Earnings

Earnings Miss: Tasly Pharmaceutical Group Co., Ltd Missed EPS By 7.6% And Analysts Are Revising Their Forecasts

Feb 26
Earnings Miss: Tasly Pharmaceutical Group Co., Ltd Missed EPS By 7.6% And Analysts Are Revising Their Forecasts

Investors Continue Waiting On Sidelines For Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Nov 17
Investors Continue Waiting On Sidelines For Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Jul 22
Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Estimating The Intrinsic Value Of Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Jun 13
Estimating The Intrinsic Value Of Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

The Market Doesn't Like What It Sees From Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Earnings Yet

May 13
The Market Doesn't Like What It Sees From Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Earnings Yet

Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively

Apr 26
Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Mar 15
Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Earnings and Revenue Growth Forecasts

SHSE:600535 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20279,7641,578N/A1,7636
12/31/20269,3721,418N/A1,6446
12/31/20258,7671,196N/A1,1726
9/30/20258,3461,0981,2361,697N/A
6/30/20258,4151,0681,2981,917N/A
3/31/20258,5049751,3621,989N/A
12/31/20248,4989561,4502,015N/A
9/30/20248,5658812,0332,676N/A
6/30/20248,6541,0262,0502,621N/A
3/31/20248,6381,1021,5512,088N/A
12/31/20238,6741,0711,9072,576N/A
9/30/20239,0761,1121,7682,287N/A
6/30/20238,9968591,9502,496N/A
3/31/20238,8475581,7872,347N/A
12/31/20228,637-2641,8752,280N/A
9/30/20228,3155341,3131,803N/A
6/30/20228,1599401,3561,782N/A
3/31/20228,0631,4781,9642,480N/A
12/31/20217,9522,3592,2292,801N/A
9/30/20217,9551,5072,2492,739N/A
6/30/20218,7791,4421,6152,145N/A
3/31/202111,3871,1541,7362,163N/A
12/31/202013,5761,1261,3821,791N/A
9/30/202016,2989699661,550N/A
6/30/202018,2057891,4672,102N/A
3/31/202018,3808487641,455N/A
12/31/201918,9981,0019491,680N/A
9/30/201919,0571,3087701,597N/A
6/30/201918,9311,519N/A1,718N/A
3/31/201918,6091,622N/A1,601N/A
12/31/201817,9901,545N/A1,494N/A
9/30/201817,9571,607N/A1,432N/A
6/30/201817,3061,545N/A1,023N/A
3/31/201816,6991,430N/A75N/A
12/31/201716,0941,377N/A-796N/A
9/30/201715,4971,312N/A-637N/A
6/30/201714,8111,248N/A-692N/A
3/31/201714,1481,218N/A298N/A
12/31/201613,9451,176N/A1,154N/A
9/30/201613,4541,263N/A759N/A
6/30/201613,3911,333N/A840N/A
3/31/201613,2941,410N/A502N/A
12/31/201513,2281,479N/A340N/A
9/30/201512,7421,447N/A351N/A
6/30/201512,6981,454N/A326N/A
3/31/201512,6401,429N/A326N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600535's forecast earnings growth (15.8% per year) is above the savings rate (2.6%).

Earnings vs Market: 600535's earnings (15.8% per year) are forecast to grow slower than the CN market (28.1% per year).

High Growth Earnings: 600535's earnings are forecast to grow, but not significantly.

Revenue vs Market: 600535's revenue (6.6% per year) is forecast to grow slower than the CN market (14.6% per year).

High Growth Revenue: 600535's revenue (6.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 600535's Return on Equity is forecast to be low in 3 years time (11.4%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/15 01:31
End of Day Share Price 2026/01/15 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tasly Pharmaceutical Group Co., Ltd is covered by 23 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Fusheng CheungChina Galaxy International Securities (Hong Kong)
Weiying TuChina International Capital Corporation Limited
Sophia ZhangChina Stock Investment Research Co. Ltd. (GZ500..com)